Abstract 5924
Background
Due to their advanced age many cancer patients with unfavorable prognosis suffer from comorbidities, and thus the risk of consuming potentially inappropriate medication (PIM). It is vital to deprescribe drugs with potential harmful effects or no short-term benefit for lowering pill.
Hence, we examined the degree of deprescription of potentially inappropriate medication (PIM) in patients suffering from cancer.
Methods
Retrospective, register-based study of all patients with newly diagnosed breast, prostate, pancreatic, and lung cancer, diagnosed at a hospital in the Capital Region of Denmark (1.8 million inhabitants) from 2012-2014. Patients with insufficient staging information or other malignancy except non-melanoma skin-cancer were excluded. Information about medication, comorbidity and mortality was extracted from the electronic health records.
PIM were defined as: acetylsalicylic acid, calcium channel blockers, statins, thiazides, and bisphosphonates. The study was approved by the Danish Patient Safety Authority (No. 3-3013-1884/1/) and the Danish Data Protection Agency (No. BFH-2016-058).
Results
Table:
1607P
Breast (n = 3,959)/prostate cancer (n = 3,535) (total n = 7,494) | Lung (n = 2,824)/pancreatic cancer (n = 617) (n = 3,441) | |
---|---|---|
Gender (Women) | 52% | 50% |
Age mean (sd) | 65 (12) | 70 (10) |
1-year Survival | 97% | 46% |
Metastatic disease | 6.7% | 52% |
Co-morbidities | ||
Diabetes | 4.0 % | 9.7 % |
Hypertension | 12 % | 23 % |
Atrial fibrillation | 4.7 % | 8.7 % |
Ischemic heart disease | 6.4 % | 11.6 % |
Heart failure | 2.2 % | 5.6 % |
Ischemic stroke | 1.5 % | 2.8 % |
Medication | 1-year deprescription/total treated§ | |
Acetylsalicylic acid | 250/1,443 (17%) | 398/928 (43%) |
Calcium channel blockers | 135/1,048 (13%) | 284/659 (43%) |
Statins | 187/1,769 (11%) | 501/1,066 (47%) |
Thiazide diuretics | 175/954 (18%) | 259/534 (49%) |
Bisphosphonates | 26/319 (8.2%) | 64/171 (37%) |
Deprescribed during the first year after cancer-diagnosis/total number of patients treated
(Patients not surviving 1 year and treatment continuing until death does not count towards deprescribed)
Conclusions
Our findings show that oncologists and physicians have a rational approach to deprescription in patients suffering from cancer with short-term (pancreatic and lung cancer) respectively long-term (breast and prostate cancer) survival rates. However, several patients were continuing potential inappropriate medications in the terminal stage of cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract